Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company devoted to pioneering their proprietary Small Molecule Nucleic Acid Hybrid (SMNH) chemistry platform to discover and develop novel therapies to improve the lives of patients worldwide. They design their SMNH compounds to bind specifically to their intended proteins, producing high therapeutic benefit over current therapies. They are committed to the highest standards of scientific excellence and integrity for the benefit of patients and the medical community.